Blockade of IL-31 by Lokivetmab prevents IL-31 from binding to its receptor and therefore inhibits IL-31-mediated cellular messaging, providing relief from dermatitis-related pruritus for at least 4 weeks after a single subcutaneous injection (1 mg/kg) in atopic dogs [15]. This evidence concerns the gene IL31 and skin disorder.